Intercept Pharmaceuticals Inc. (NASDAQ:ICPT)’s share price traded down 3.6% during mid-day trading on Wednesday . The stock traded as low as $161.62 and last traded at $163.89, with a volume of 458,357 shares trading hands. The stock had previously closed at $170.01.

Several equities analysts have recently issued reports on the company. Wedbush reissued an “outperform” rating and set a $239.00 target price on shares of Intercept Pharmaceuticals in a research note on Monday, August 22nd. JMP Securities reissued a “buy” rating on shares of Intercept Pharmaceuticals in a research note on Thursday, August 18th. FBR & Co reissued a “market perform” rating and set a $200.00 target price on shares of Intercept Pharmaceuticals in a research note on Thursday, August 18th. Credit Suisse Group AG reaffirmed a “buy” rating and issued a $200.00 price target on shares of Intercept Pharmaceuticals in a research note on Friday, August 5th. Finally, Laidlaw cut Intercept Pharmaceuticals from a “buy” rating to a “sell” rating and reduced their price target for the stock from $345.00 to $105.00 in a research note on Friday, August 5th. Five research analysts have rated the stock with a sell rating, five have given a hold rating and ten have given a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $177.67.

The firm’s 50-day moving average price is $158.03 and its 200-day moving average price is $147.11. The stock’s market cap is $4.17 billion.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/intercept-pharmaceuticals-inc-icpt-shares-down-3-6.html

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($3.14) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($3.69) by $0.55. The business earned $5.52 million during the quarter, compared to analyst estimates of $1.72 million. Intercept Pharmaceuticals had a negative return on equity of 50.58% and a negative net margin of 5,003.95%. Intercept Pharmaceuticals’s revenue was up 1140.4% on a year-over-year basis. During the same period in the previous year, the company posted ($1.99) EPS. On average, analysts forecast that Intercept Pharmaceuticals Inc. will post ($16.31) EPS for the current year.

In other news, insider Lisa Bright sold 246 shares of Intercept Pharmaceuticals stock in a transaction on Thursday, August 25th. The stock was sold at an average price of $159.00, for a total value of $39,114.00. Following the transaction, the insider now directly owns 18,460 shares in the company, valued at approximately $2,935,140. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Mark Pruzanski sold 714 shares of Intercept Pharmaceuticals stock in a transaction on Tuesday, July 5th. The shares were sold at an average price of $145.11, for a total value of $103,608.54. The disclosure for this sale can be found here. Company insiders own 9.20% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. CENTRAL TRUST Co bought a new position in shares of Intercept Pharmaceuticals during the second quarter worth about $107,000. Legal & General Group Plc increased its position in shares of Intercept Pharmaceuticals by 15.8% in the first quarter. Legal & General Group Plc now owns 1,144 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 156 shares in the last quarter. Metropolitan Life Insurance Co. NY increased its position in shares of Intercept Pharmaceuticals by 3.2% in the second quarter. Metropolitan Life Insurance Co. NY now owns 1,234 shares of the biopharmaceutical company’s stock worth $176,000 after buying an additional 38 shares in the last quarter. Pacer Advisors Inc. bought a new position in shares of Intercept Pharmaceuticals during the second quarter worth about $180,000. Finally, IBM Retirement Fund increased its position in shares of Intercept Pharmaceuticals by 3.6% in the second quarter. IBM Retirement Fund now owns 1,657 shares of the biopharmaceutical company’s stock worth $236,000 after buying an additional 58 shares in the last quarter. Institutional investors and hedge funds own 81.86% of the company’s stock.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

5 Day Chart for NASDAQ:ICPT

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.